Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:25:39.622Z.
Consensus retrieved: 2026-10-06T08:42:24.361Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:25:39.622Z.
Quote observation: 2026-10-06T16:25:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Forward PE Ratio (N/A) = Dated Quote Price ($6.87) / Consensus Forward EPS ($-3.26)
FORWARD PE RATIO
N/A
Alumis Inc.
Market Cap
$848.46M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alumis Inc. (ALMS) | $848.46M | N/A |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $847.20M | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $841.31M | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $840.81M | 15.96 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $859.14M | N/A |
| SI-BONE, Inc. (SIBN)vs › | $865.70M | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $825.95M | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $824.96M | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $876.35M | 13.81 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $882.95M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.87, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.27 | $-3.48 – $-3.07 | 6 | n/m |
| 2027-12-31 | $-2.82 | $-3.07 – $-2.60 | 6 | n/m |
| 2028-12-31 | $-2.08 | $-2.88 – $-0.97 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
